Keyphrases
Docetaxel
100%
Abiraterone
100%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
100%
Optimal Sequence
100%
Overall Survival
33%
Propensity Score
33%
Treatment Sequence
33%
Chemotherapy
22%
Between-group
22%
Progression-free Survival
22%
PFS2
22%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
11%
Tumor
11%
Patient Preference
11%
Prostate Cancer Patients
11%
Multivariate Analysis
11%
Comorbidity
11%
Patient Characteristics
11%
Disease Pattern
11%
Retrospective Analysis
11%
Clinical Benefit
11%
Recent Advances
11%
FDA-approved Drugs
11%
Outcome-based
11%
Optimal Treatment
11%
Multivariable Model
11%
Early Use
11%
Univariate Analysis
11%
Baseline Characteristics
11%
Johns Hopkins
11%
Survival Benefit
11%
Patients Included
11%
Life-sustaining Treatment
11%
Reverse Sequence
11%
End-organ Function
11%
Gleason
11%
Hormonal Therapy
11%
Radiopharmaceuticals
11%
Difference Basis
11%
CHAARTED
11%
Clinical Outcomes
11%
Kaplan-Meier Analysis
11%
Metastatic Burden
11%
Pharmacology, Toxicology and Pharmaceutical Science
Docetaxel
100%
Castration Resistant Prostate Cancer
100%
Abiraterone
100%
Overall Survival
33%
Chemotherapy
22%
Progression Free Survival
22%
Hormone Cancer Therapy
11%
Prostate Cancer
11%
Biological Marker
11%
Side Effect
11%
Radiopharmaceutical Agent
11%
Neoplasm
11%
Immunotherapy
11%
Comorbidity
11%
Diseases
11%
Neuroscience
Docetaxel
100%
Prostate
100%
Abiraterone
100%
Radiopharmaceutical
11%
Immunotherapy
11%
Hormone Therapy
11%
Comorbidity
11%